DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Colon Cancer - Pipeline Review, H1 2016" report to their offering.
Colon Cancer Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.
Colon Cancer pipeline therapeutics constitutes close to 260 molecules. Out of which approximately 197 molecules are developed by Companies and remaining by the Universities Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 25, 3, 148, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 42 and 16 molecules, respectively.
Colon Cancer - Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Colon Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects.
Companies Mentioned
- ACF Pharmaceuticals, LLC
- Adgero Biopharmaceuticals, Inc.
- Aduro BioTech, Inc.
- Advanced Proteome Therapeutics Corporation
- Advenchen Laboratories, LLC
- Agenus, Inc.
- AGV Discovery, SAS
- AIMM Therapeutics B.V.
- Ambrx, Inc.
- Anavex Life Sciences Corp.
- AndroScience Corporation
- Aphios Corporation
- Aposense Ltd.
- Aptose Biosciences Inc.
- Asana BioSciences, LLC
- AstraZeneca Plc
- Aurigene Discovery Technologies Limited
- BCN Biosciences L.L.C.
- Bio-Path Holdings, Inc.
- Biogazelle
- Bioncotech Therapeutics S.L.
- Blirt S.A.
- Boehringer Ingelheim GmbH
- Can-Fite BioPharma Ltd.
- Celprogen, Inc.
- Celyad SA
- Chiome Bioscience, Inc.
- Critical Outcome Technologies Inc.
- Cyclacel Pharmaceuticals, Inc.
- CytomX Therapeutics, Inc.
- Cytune Pharma SAS
- CZ BioMed Corp
- DEKK-TEC, Inc.
- Digna Biotech, S.L.
- Eli Lilly and Company
For more information visit http://www.researchandmarkets.com/research/2vcsbn/colon_cancer
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
